Sleep Duration, Melatonin, and Breast Cancer: Compliment and Complement

To the Editor:

In an interesting study, Verkasalo et al. (1) found some support for lower breast cancer risks in long sleepers in Finland. The authors appropriately embedded their discussion in the existing literature, insofar as they point to prior studies into possible links between long sleep and mortality. Indeed, the recent review by Youngstedt and Kripke (2) evinced that sleeping beyond 8 hours could be associated with increased mortality, and this should be diligently considered when zeroing in on possible implications of long sleep on public health. Adding further to this evidence of complicated study results is a recent study by Patel et al. (3).

A few remarks to what the authors of the present study “hypothesized,” to this novel study approach and to existing literature may be in order, though. In their abstract, they wrote that “we hypothesized that there is an inverse association between sleep duration and breast cancer risk, possibly due to greater overall melatonin production in longer sleepers.” May I kindly point to a 2002 publication in which I suggested in detail to employ “individuals’ cumulative time at sleep” when zeroing in on possible implications of long sleep on public health. Adding further to this evidence of complicated study results is a recent study by Patel et al. (3).

Clearly, the epidemiologic study by Verkasalo et al. is a good start into research of the issues concerned (i.e., sleep duration, light-at-night, melatonin, and breast cancer incidence). Equally clearly, the hypothesis statement in the abstract could, and possibly should, be complemented by a reference to the first proposal of the study idea, which was discussed at an international symposium (5) and published in Neuroendocrinology Letters 3 years ago (4).

In Response:

The hypothesis that sleep duration would be associated with breast cancer risk rests primarily on the work of Wehr et al. on sleep duration and melatonin production (for instance, ref. 1), which we cited in our paper (2). In 1996, Stevens and Davis (3) discussed sleep length and melatonin production in the context of breast cancer, although the specific prediction that sleep duration would be associated with risk was not stated. Erren (4) and Stevens (5) did, however, both state the sleep duration prediction explicitly. It was an oversight not to cite these two papers.

Pia K. Verkasalo
Department of Environmental Health, National Public Health Institute, Espoo, Finland

Kirsi Lillberg
Department of Public Health, University of Turku, Turku, Finland

Richard G. Stevens
Department of Community Medicine, University of Connecticut Health Center, Farmington, Connecticut

Christer Hulin
Finnish Institute of Occupational Health, Helsinki, Finland

Markku Partinen
Runneko Research Centre, Espoo, Finland

Markku Koskenvuo
Department of Public Health, University of Helsinki, Helsinki, Finland

Jaakko Kaprio
Department of Public Health, University of Helsinki, Finland and Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland

References

Sleep Duration, Melatonin, and Breast Cancer: Compliment and Complement

Thomas C. Erren


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/66/7/3954.1

Cited articles
This article cites 10 articles, 2 of which you can access for free at:
http://cancerres.aacrjournals.org/content/66/7/3954.1.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.